Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005619 · ClinicalTrials.gov registry record
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
A clinical trial of Leukemia, sponsored by Northwestern University.
- Completed
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT00005619 is a study of Leukemia that has completed, run by Northwestern University. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00005619, a study of Leukemia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia. PURPOSE: Diagnostic trial to determine the effectiveness of analyzing blood and bone marrow to detect residual disease in patients who have previously treated hairy cell leukemia.
Conditions Studied
Interventions
- GENETIC polymerase chain reaction
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2000-02 |
| Est. Completion | 2001-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005619
The ClinicalTrials.gov registry entry for NCT00005619 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which polymerase chain reaction is the first listed.
NCT00005619 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00005619 about?
NCT00005619 is a clinical study titled "Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia". RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia. PURPOSE: Diagnostic trial to determine the effectiveness of analyzing blood and bone marrow to detect residual disease in patients who have previously treated hairy ce...
What is the current status of trial NCT00005619?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2000-02. Estimated completion is 2001-08.
What conditions does trial NCT00005619 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00005619?
The interventions under investigation include: polymerase chain reaction (GENETIC), immunohistochemistry staining method (OTHER), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00005619?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005619 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.